The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Advisory Board Appointment

18 Aug 2021 07:00

RNS Number : 9416I
DeepMatter Group PLC
18 August 2021
 

18 August 2021

 

DeepMatter Group Plc

DeepMatter CEO appointed Chairman of Industrial Advisory Board at Imperial College

DeepMatter Group Plc (AIM: DMTR, "DeepMatter", the "Group"), which focuses on digitalising chemistry, announces that its CEO, Mark Warne, has been invited to chair the Industrial Advisory Board (IAB) at Imperial College's EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology (CDT), for the next two years.

Mark's principal role will be to liaise closely with the CDT's network of industrial partners, including AstraZeneca, Bayer, BASF, GlaxoSmithKline, IBM, The Janssen Pharmaceutical Companies of Johnson & Johnson, Mettler-Toledo, Syngenta, and Pfizer. 

These partners provide industrial advice and feedback on the CDT's research direction as well as making recommendations in the areas of chemistry, chemical engineering and data science.

Mark Warne, DeepMatter CEO, commented:

"This appointment will enable me to work closely with a number of multinational pharma companies and Key Opinion Leaders - all of whom are committed to integrating chemistry with technology and sharing their expertise and experience with the chemists of the future.

"This appointment is a further validation of DeepMatter's position at the centre of the digitalisation of chemistry and the development of big data and analytics for the chemists in early-stage formulation."

The CDT is made up of a multi-disciplinary team of internationally-leading researchers at Imperial College. It benefits from significant infrastructural and capital investment on its state-of-the-art technology and facilities such as The Centre for Rapid Online Analysis of Reactions (ROAR).

The CDT aims to engage with the Centres of Excellence in the US and Europe, to deliver a unique multi-faceted training programme in order to improve the skills, employability and productivity of the graduates and to equip them for future academic and industrial roles.

Jinata Subba, EPSRC CDT Programme Manager, Dept of Chemistry, Imperial College, added:

 "DeepMatter's knowledge and experience of automation in chemistry will help us on our mission to transform synthetic chemistry into a truly data-driven discipline. Automation enables researchers to gather and share huge amounts of data about chemical reactions, which can then be used to optimize processes and even forecast the outcomes of entirely new reactions.

"There is a skills gap between academic training and the experimental methods used routinely in industry. At Imperial College our programme aims to equip students for the future of synthetic chemistry. The advice and feedback from the Industrial Advisory Board is proving invaluable.

"DeepMatter's mission of digitising chemistry using cutting edge analytical instruments and Machine Learning techniques resonates with the way we are pioneering this approach to training."

 

For more information, please contact:

 

DeepMatter Group PlcMark Warne, Chief Executive Officer 0141 548 8156

Canaccord Genuity Limited (Nominated Advisor and Broker) 020 7523 8000Bobbie Hilliam

Meare Consulting 07990 858548Adrian Duffield

 

About DeepMatter Group Plc 

DeepMatter is building and commercialising the most powerful data platforms, to enable scientists to easily perform and optimise chemical reactions, by increasingly integrating chemistry with technology. Ultimately this will allow the greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics.

Visit: www.deepmatter.io and follow @deepmattergroup

 

About the EPSRC Centre for Doctoral Training in Next Generation Synthesis & Reaction Technology

The mission of the Next Generation Synthesis & Reaction Technology CDT is to educate a critical mass of researchers equipped to respond to future research challenges and opportunities created by the data-revolution. The aim is to train highly qualified researchers with the ability to collect data using automated, high-throughput reaction platforms, and to apply quantitative and statistical approaches to data analysis and utilisation. This will be achieved by incorporating cross-disciplinary skills from engineering, as well as computing, statistics, and informatics into a chemistry graduate programme, which are largely lacking from existing doctoral training in synthetic chemistry.

Visit: www.imperial.ac.uk/next-generation-synthesis-reaction-technology/the-cdt-programme/

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRABUGDIBGBDGBR
Date   Source Headline
13th Apr 20167:00 amRNSPreliminary Results
21st Oct 20157:00 amRNSCompletion of Capital Reorganisation
7th Oct 20151:56 pmRNSResult of Court Hearing
29th Sep 20153:33 pmRNSHolding(s) in Company
28th Sep 201510:02 amRNSHolding(s) in Company
16th Sep 20157:00 amRNSChange of Name
15th Sep 20153:32 pmRNSHolding(s) in Company
15th Sep 201510:02 amRNSDirectors' Interest in Shares
15th Sep 201510:01 amRNSDirectorate Changes
15th Sep 201510:00 amRNSCompletion of Placing and Acquisition
11th Sep 201510:00 amRNSApplication for Admission
10th Sep 201511:16 amRNSResult of General Meeting
25th Aug 20155:10 pmRNSHalf Yearly Report
25th Aug 20155:05 pmRNSAcquisition and related matters
7th Jul 20157:00 amRNSChange of Name
30th Jun 201512:10 pmRNSResult of AGM
4th Jun 20158:35 amRNSReplacement: Final Results
4th Jun 20157:00 amRNSDirectorate Change
4th Jun 20157:00 amRNSFinal Results
8th Jan 20155:56 pmRNSHolding(s) in Company
9th Sep 20147:00 amRNSCompletion of investment in subsidiary
29th Aug 20147:00 amRNSHalf Yearly Report
14th Jul 201411:00 amRNSResult of AGM
30th Jun 20147:00 amRNSFirst commercial sale
17th Jun 20147:00 amRNSFinal Results
17th Mar 20147:00 amRNSGraphene Functionalisation Capabilities
3rd Feb 20147:00 amRNSProject Announcement
24th Jan 20147:00 amRNSOAS launches OntoTM Development Pack for customer
18th Nov 20135:43 pmRNSHolding(s) in Company
30th Oct 20137:00 amRNSDirectorate Change
18th Oct 20137:00 amRNSChange to substantial shareholdings
20th Sep 20137:00 amRNSDirectorate Change
28th Aug 20139:40 amRNSHalf Yearly Report
13th Jun 20135:30 pmRNSAGM Statement
1st May 20137:00 amRNSFinal Results
12th Apr 20131:10 pmRNSHolding(s) in Company
13th Mar 20138:42 amRNSHolding(s) in Company
12th Mar 20138:37 amRNSHolding(s) in Company
6th Mar 20134:03 pmRNSHolding(s) in Company
9th Jan 20137:00 amRNSTechnical Advisory Board Enhanced
7th Jan 20134:25 pmRNSHolding(s) in Company
20th Dec 20121:55 pmRNSHolding(s) in Company
5th Dec 20125:33 pmRNSHolding(s) in Company
12th Nov 20128:51 amRNSHolding(s) in Company
3rd Oct 20127:00 amRNSDirectors' Interest in Shares
26th Sep 20127:00 amRNSInterim Statement
24th Sep 20129:58 amRNSHolding(s) in Company
17th Sep 20129:26 amRNSHolding(s) in Company
1st Aug 20127:00 amRNSAppointment of CEO
15th Jun 201212:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.